Paloma Partners Management Co Invests $200,000 in Smith & Nephew SNATS, Inc. (NYSE:SNN)

Paloma Partners Management Co purchased a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,468 shares of the medical equipment provider’s stock, valued at approximately $200,000.

Other institutional investors also recently added to or reduced their stakes in the company. Wrapmanager Inc. increased its position in Smith & Nephew SNATS by 12.2% in the first quarter. Wrapmanager Inc. now owns 9,971 shares of the medical equipment provider’s stock worth $308,000 after buying an additional 1,082 shares during the last quarter. Eqis Capital Management Inc. increased its position in Smith & Nephew SNATS by 35.6% in the first quarter. Eqis Capital Management Inc. now owns 39,587 shares of the medical equipment provider’s stock worth $1,224,000 after buying an additional 10,394 shares during the last quarter. Geneva Advisors LLC increased its position in Smith & Nephew SNATS by 4.2% in the first quarter. Geneva Advisors LLC now owns 34,027 shares of the medical equipment provider’s stock worth $1,052,000 after buying an additional 1,387 shares during the last quarter. Wells Fargo & Company MN increased its position in Smith & Nephew SNATS by 21.4% in the first quarter. Wells Fargo & Company MN now owns 429,522 shares of the medical equipment provider’s stock worth $13,285,000 after buying an additional 75,572 shares during the last quarter. Finally, BB&T Corp increased its position in Smith & Nephew SNATS by 4.3% in the first quarter. BB&T Corp now owns 79,804 shares of the medical equipment provider’s stock worth $2,468,000 after buying an additional 3,299 shares during the last quarter. 7.23% of the stock is owned by institutional investors.

Smith & Nephew SNATS, Inc. (NYSE SNN) opened at 35.12 on Friday. The company has a market cap of $15.38 billion, a P/E ratio of 17.88 and a beta of 0.76. The firm’s 50 day moving average is $34.83 and its 200-day moving average is $32.75. Smith & Nephew SNATS, Inc. has a 52 week low of $26.97 and a 52 week high of $35.85.

COPYRIGHT VIOLATION WARNING: “[[title]]” was originally reported by [[site]] and is owned by of [[site]]. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at [[permalink]].

A number of research firms recently issued reports on SNN. Zacks Investment Research raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research note on Wednesday, June 7th. BidaskClub raised shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Six equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Smith & Nephew SNATS currently has an average rating of “Hold” and an average target price of $38.00.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.